Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional dose PCV10 mass campaign in Niger
NCT05175014Phase 4Completed
- Sponsor
- Illumina
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of SIILPCV10 in pneumococcal disease, sponsored by Illumina. Started Dec 2021; status: completed.
02
Drugs
SIILPCV10
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05175014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175014.